Hormone Health · Clinical Protocol
Tirzepatide for Perimenopause
Women in Perimenopause · Metabolic + Hormonal Optimization · 12-Week Protocol
Concentration: 10 mg/mL · Route: Subcutaneous · Once Weekly
A conservative, low-and-slow Tirzepatide titration built specifically for the perimenopausal window — where fluctuating estrogen disrupts insulin sensitivity, appetite regulation, and fat distribution. Patience in titration produces better long-term adherence and outcomes.
Instant digital download · Clinical reference document
Why Perimenopause Requires a Different Approach
Designed for Hormonal Volatility
Perimenopausal physiology is hormonally volatile — side effects that appear manageable in younger or post-menopausal women can be amplified during this transitional window. This protocol accounts for that reality at every step.
The Protocol
Four Phases. Twelve Weeks.
Foundation Phase
Ultra-low dose introduction to assess individual tolerance. Perimenopausal physiology requires a gentler start than standard protocols.
Titration Phase
Gradual escalation while monitoring GI response, energy, and hormonal symptoms. Dose holds are expected and encouraged.
Optimization Phase
Approaching therapeutic range for meaningful metabolic effect. Fat loss, improved glucose regulation, and appetite control become measurable.
Maintenance Phase
Peak dose for sustained results. Focus shifts to habit integration, metabolic monitoring, and planning for long-term protocol continuation.
Get the Protocol
Instant Digital Access
Tirzepatide Perimenopause Protocol™
Instant digital download · Yours forever
- 12-Week Conservative Titration Protocol (PDF/DOCX)
- Week-by-Week Dosing Schedule at 10 mg/mL
- Perimenopausal Physiology Overview
- GI Side Effect Management Guide
- Hormonal Interaction Notes (Estrogen / Insulin)
- Injection Technique & Site Rotation Guide
- Lifestyle & Nutrition Recommendations
- Monitoring Checklist & Progress Tracker
- Lifetime access + all future updates
🔒 Secure checkout via Stripe · Instant delivery
This protocol is intended for use under clinical supervision. Tirzepatide is a prescription medication — all dosing decisions must be individualized by a licensed provider based on patient history and labs. This document is a clinical reference tool, not a substitute for medical advice.
